As of April 19, 2025, Lyell Immunopharma (LYEL) has a market cap of $0.13 billion USD. According to our data, Lyell Immunopharma is ranked No.7380 in global market value.
Year | Market Cap | %Change |
---|---|---|
Apr 19, 2025 | $0.13 B |
-31.54%
|
Dec 31, 2024 | $0.19 B |
-67.01%
|
Dec 29, 2023 | $0.57 B |
-44.09%
|
Dec 30, 2022 | $1.01 B |
-55.17%
|
Dec 31, 2021 | $2.26 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
![]() Allogene Therapeutics
ALLO
|
$0.32 B |
-0.000 M
|
![]() USA
|
![]() Adaptimmune Therapeutics
ADAP
|
$61.27 M |
0.051 M
|
![]() UK
|
![]() Atara Biotherapeutics
ATRA
|
$36.15 M |
0.000 M
|
![]() USA
|
![]() Cellectis
CLLS
|
$0.20 B |
49.857 M
|
![]() France
|
![]() CRISPR Therapeutics
CRSP
|
$3.26 B |
0.000 M
|
![]() Switzerland
|
![]() Editas Medicine
EDIT
|
$0.11 B |
-0.000 M
|
![]() USA
|
![]() Intellia Therapeutics
NTLA
|
$0.75 B |
-0.000 M
|
![]() USA
|
![]() Gilead Sciences
GILD
|
$130.32 B |
-0.001 M
|
![]() USA
|
![]() Poseida Therapeutics
PSTX
|
$0.93 B |
0.000 M
|
![]() USA
|
![]() Sana Biotechnology
SANA
|
$0.37 B |
0.000 M
|
![]() USA
|
![]() Sangamo Therapeutics
SGMO
|
$0.16 B |
-0.989 M
|
![]() USA
|
![]() bluebird bio
BLUE
|
$40.53 M |
0.000 M
|
![]() USA
|
![]() Fate Therapeutics
FATE
|
$0.13 B |
0.000 M
|
![]() USA
|
Market Cap | = | LYEL Stock Price | * | LYEL Shares Outstanding |
= | $0.43 | * | 0.30 B | |
= | $0.13 B |